In many cases, early-stage prostate cancer will not spread or cause any problems or side effects for a long time, if ever. That’s why your health care provider may suggest active surveillance. This is ...

Jason Junkins, M.D., and his wife, Angela For local urgent care physician Jason Junkins, M.D., prostate cancer was not on his ...

During a live event, Jahan Aghalar, MD, discussed key NCCN-recommended oral therapies and landmark trials for metastatic ...

Diffusion basis spectrum imaging combined with AI enhances diagnostic accuracy for prostate cancer A study published in the ...

Importance and Determinants of Gleason Score Undergrading on Biopsy Sample of Prostate Cancer in a Population-based Study ...

The Interdisciplinary Genitourinary Cancer Forum 2025, held between June 19 – 21, 2025 held in St. Petersburg, Florida, United States, was host to the Prostate Cancer Session 7: Non-metastatic ...

Effective from 1 October 2025, CMS and commercial health insurers will recognise the HCPCS Level II code A9616 assigned for reimbursement of Gozellix. The assignment of the code is a significant ...

Telix Pharmaceuticals’ Illuccix gets US FDA label expansion to add patient selection for radioligand therapy: Melbourne, Australia Wednesday, June 25, 2025, 17:00 Hrs [IST] Melb ...

Illuccix® (kit for the preparation of gallium-68 ( 68 Ga) gozetotide injection), Telix’s first generation PSMA-PET imaging agent, is approved and commercially available in multiple countries globally.

Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...